10-1074-LS
10-1074-LS is a biological therapy with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
bNAbs and Anti-PD-1 in HIV
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
Clinical Trials (7)
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
bNAbs and Anti-PD-1 in HIV
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7